Month: March 2025

SHANGHAI, March 26, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (“NPC”) has been approved by the Singapore Health Sciences Authority (the HSA). Toripalimab has become the first and only approved immuno-oncology treatment for NPC in Singapore. NPC is a malignant tumor that occurs in the epithelium mucosae of the nasopharynx and is one of the most...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES/ VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTC: YMMCF) (“Yukon Metals” or the “Company”) is pleased to announce that it has entered into an agreement with Cormark Securities Inc. and Canaccord Genuity Corp. (the “Co-Agents”) to act as co-agents in connection with a “best efforts” private placement for aggregate gross proceeds of up to approximately C$5 million (the “Offering”). The Offering will consist of the issuance and sale of up to 9,090,909 units of the Company (the “Units”) at a price of C$0.55 per Unit (the “Issue Price”). Each Unit will consist of one common share of the Company (each, a “Unit Share”) and...

PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, reiterates that it has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and will continue to vigorously pursue its infringement action on appeal against Aveva Drug Delivery Systems, Inc. (“Aveva”). In May 2022, Scilex received notice that a pharmaceutical maker, Aveva and its former related entities, Apotex Corp. and Apotex Inc. (collectively, the “Apotex Parties”),...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food and Drug Administration (FDA) for any indication, is now available for purchase in the United States. Ryoncil® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. The recommended dosage of Ryoncil® for treatment of pediatric SR-aGvHD is 2×106 MSC/kg body weight per intravenous infusion given twice per week for 4 consecutive weeks. To assist patients and institutions with insurance coverage, financial...

QUEBEC CITY, Canada, March 26, 2025 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech” or the “Corporation”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-powered low-level sensor fusion and perception software technology, LeddarVision™, announces the voting results of its annual general and special meeting of shareholders held on March 26, 2025 (the “Meeting”). Shareholders voted on various proposals and elected directors to the board. Key Highlights of the Meeting 1. Election of Directors: The full slate of six directors was elected to serve until the next annual meeting of shareholders or until a successor is elected or appointed.Nominee Votes For % of Voted Votes Against % of VotedFrantz Saintellemy 22,429,293 99.69% 68,631 0.31%Charles Boulanger 22,392,108 99.53% 105,816 0.47%Derek...

VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company”) announces, further to its news release dated March 20, 2025, that the consolidation of its common shares (the “Common Shares”) on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Consolidation”) will have a record date of April 1, 2025. The Company currently has 82,810,561 Common Shares issued and outstanding, and following the Consolidation, will have approximately 8,281,056 Common Shares issued and outstanding, prior to rounding of fractional Common Shares. No fractional Common Shares will be issued as a result of the proposed Consolidation. Any fractional Common Shares resulting from the Consolidation will be rounded up in the...

HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) — Itafos Inc. (TSX-V: IFOS) (the “Company”) announced today that the Company has granted, in the aggregate, 773,037 restricted share units (“RSUs”) to directors and officers of the Company. The RSUs are scheduled to vest on a one-third per annum basis over a three-year period. Certain grants are also subject to the fulfilment of additional performance conditions. Each vested RSU entitles the holder to receive one share of the Company’s common stock or a cash payment equal to the equivalent of one share of the Company’s common stock on the date of vesting. All grants of RSUs are subject to the Company’s Restricted Share Unit Plan. The grants were made as part of the Company’s annual compensation process and are intended to appropriately reward past and ongoing contributions and to incentivize...

Receives Court Approval for First Day Motions to Support Ongoing Business Operations SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) — 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the “Court”) for its “first day” motions related to 23andMe’s voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the “DIP Facility”). 23andMe remains committed to its customers while it seeks...